{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,30]],"date-time":"2023-12-30T02:40:13Z","timestamp":1703904013737},"reference-count":129,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2001,10,1]],"date-time":"2001-10-01T00:00:00Z","timestamp":1001894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pulmonary Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2001,10]]},"DOI":"10.1006\/pupt.2001.0302","type":"journal-article","created":{"date-parts":[[2002,9,18]],"date-time":"2002-09-18T21:19:16Z","timestamp":1032383956000},"page":"367-381","source":"Crossref","is-referenced-by-count":8,"title":["Advances in the Research and Development of Chemotherapeutic Agents for Respiratory Tract Bacterial Infections"],"prefix":"10.1006","volume":"14","author":[{"given":"Mario","family":"Cazzola","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Blasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Centanni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio Ferdinando","family":"Donner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Allegra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1006\/pupt.2001.0302_RF1","first-page":"S651","article-title":"Emergence of antibiotic resistance in upper and lower respiratory tract infections","volume":"5 (11 Suppl)","author":"Jacobs","year":"1999","journal-title":"Am J Manag Care"},{"key":"10.1006\/pupt.2001.0302_RF2","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1128\/CMR.6.4.428","article-title":"An overview to nosocomial infections, including the role of the microbiology laboratory","volume":"6","author":"Emori","year":"1993","journal-title":"Clin Microbiol Rev"},{"key":"10.1006\/pupt.2001.0302_RF3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/jac\/40.1.135","article-title":"Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility","volume":"40","author":"Hiramatsu","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"10.1006\/pupt.2001.0302_RF4","first-page":"624","article-title":"Reduced susceptibility of Staphylococcus aureus to vancomycin \u2013 Japan, 1996","volume":"46","author":"Centers for Disease Control and Prevention","year":"1997","journal-title":"Morbid Mortal Weekly Rep"},{"key":"10.1006\/pupt.2001.0302_RF5","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0732-8893(97)00195-8","article-title":"Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in the 1996\u20131997 respiratory season. The Laboratory Investigator Group","volume":"29","author":"Thornsberry","year":"1997","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1006\/pupt.2001.0302_RF6","doi-asserted-by":"crossref","unstructured":"Thornsberry, C, Ogilvie, PT, Holley, HP Jr, Sahm, DF, Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates to 26 antimicrobial agents: a prospective US study, Antimicrob Agents Chemother 1999, 43, 2612, 2623","DOI":"10.1128\/AAC.43.11.2612"},{"key":"10.1006\/pupt.2001.0302_RF7","first-page":"42","article-title":"The European experience with antibiotic resistance in respiratory pathogens","volume":"16","author":"Schito","year":"1999","journal-title":"Infect Med"},{"key":"10.1006\/pupt.2001.0302_RF8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-199600511-00003","article-title":"Emergence of resistance to antimicrobial agents in gram-positive bacteria \u2013 pneumococci","volume":"51 (Suppl. 1)","author":"Appelbaum","year":"1996","journal-title":"Drugs"},{"key":"10.1006\/pupt.2001.0302_RF9","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/clinids\/15.1.84","article-title":"Antimicrobial resistance in Streptococcus pneumoniae: a South African perspective","volume":"15","author":"Koornhof","year":"1992","journal-title":"Clin Infect Dis"},{"key":"10.1006\/pupt.2001.0302_RF10","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1128\/AAC.39.12.2667","article-title":"Emergence of multiple antibiotic-resistant Streptococcus pneumoniae in Hong Kong","volume":"39","author":"Kam","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1006\/pupt.2001.0302_RF11","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/clinids\/15.1.95","article-title":"Antimicrobial resistance in Streptococcus pneumoniae: an epidemiological survey in France, 1970\u20131990","volume":"15","author":"Geslin","year":"1992","journal-title":"Clin Infect Dis"},{"key":"10.1006\/pupt.2001.0302_RF12","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1086\/516945","article-title":"Spread of multidrug-resistant Streptococcus pneumoniae in South Korea","volume":"25","author":"Song","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.1006\/pupt.2001.0302_RF13","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1086\/514953","article-title":"Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program","volume":"27","author":"Doern","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1006\/pupt.2001.0302_RF14","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1086\/513628","article-title":"Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae a multicenter study","volume":"24","author":"Clavo-Sanchez","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.1006\/pupt.2001.0302_RF15","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1053\/jhin.1999.0580","article-title":"Hospital-related outbreak of infection with multidrug-resistant Streptococcus pneumoniae in the Netherlands","volume":"42","author":"De Galan","year":"1999","journal-title":"J Hosp Infect"},{"key":"10.1006\/pupt.2001.0302_RF16","doi-asserted-by":"crossref","first-page":"578","DOI":"10.2307\/30141784","article-title":"Is Streptococcus pneumoniae a nosocomially acquired pathogen?","volume":"19","author":"Paradisi","year":"1998","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1006\/pupt.2001.0302_RF17","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1128\/AAC.41.2.292","article-title":"Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of \u03b2-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study","volume":"41","author":"Doern","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1006\/pupt.2001.0302_RF18","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1056\/NEJM199611073351907","article-title":"Antimicrobial-drug resistance","volume":"335","author":"Gold","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1006\/pupt.2001.0302_RF19","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/jac\/38.3.409","article-title":"Antibiotic resistance and production of extended-spectrum \u03b2-lactamases amongst Klebsiella species from intensive care units in Europe","volume":"38","author":"Livermore","year":"1996","journal-title":"J Antimicrob Chemother"},{"key":"10.1006\/pupt.2001.0302_RF20","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1128\/JCM.35.1.152-160.1997","article-title":"Molecular epidemiology of an outbreak of multidrug-resistant Enterobacter aerogenes infections and in vivo emergence of imipenem resistance","volume":"35","author":"De Gheldre","year":"1997","journal-title":"J Clin Microbiol"},{"key":"10.1006\/pupt.2001.0302_RF21","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/infdis\/170.2.377","article-title":"Pseudomonas aeruginosa outbreak in a burn unit: role of antimicrobials in the emergence of multiply resistant strains","volume":"170","author":"Richard","year":"1994","journal-title":"J Infect Dis"},{"key":"10.1006\/pupt.2001.0302_RF22","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1099\/00222615-46-9-721","article-title":"Clinical importance and antibiotic resistance of Acinetobacter spp","volume":"46","author":"Towner","year":"1997","journal-title":"J Med Microbiol"},{"key":"10.1006\/pupt.2001.0302_RF23","doi-asserted-by":"crossref","first-page":"236","DOI":"10.2307\/30141027","article-title":"Nosocomial infection caused by antibiotic-resistant organisms in the intensive-care unit","volume":"17","author":"Flaherty","year":"1996","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1006\/pupt.2001.0302_RF24","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1128\/AAC.41.3.497","article-title":"The search for antimicrobial agents effective against bacteria resistant to multiple antibiotics","volume":"41","author":"Chopra","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1006\/pupt.2001.0302_RF25","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0966-842X(97)01128-1","article-title":"New strategies for antibacterial drug design","volume":"5","author":"Knowles","year":"1997","journal-title":"Trends Microbiol"},{"key":"10.1006\/pupt.2001.0302_RF26","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1369-5274(99)00003-X","article-title":"What's new in the antibiotic pipeline","volume":"2","author":"Lee","year":"1999","journal-title":"Curr Opin Microbiol"},{"key":"10.1006\/pupt.2001.0302_RF27","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.1086\/514902","article-title":"Antibiotic resistance: lessons for the future","volume":"27 (Suppl 1)","author":"Moellering","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1006\/pupt.2001.0302_RF28","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S1369-5274(98)80080-5","article-title":"Research and development of antibacterial agents","volume":"1","author":"Chopra","year":"1998","journal-title":"Curr Opin Microbiol"},{"key":"10.1006\/pupt.2001.0302_RF29","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/jac\/44.2.201","article-title":"Structures of existing and new quinolones and relationship to bactericidal activity against Streptococcus pneumoniae","volume":"44","author":"Mitsuyama","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1006\/pupt.2001.0302_RF30","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1128\/AAC.44.2.320-325.2000","article-title":"Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisometase IV to gyrase","volume":"44","author":"Alovero","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1006\/pupt.2001.0302_RF31","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/jac\/41.4.481","article-title":"Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus","volume":"41","author":"Schmitz","year":"1998","journal-title":"J Antimicrob Chemother"},{"key":"10.1006\/pupt.2001.0302_RF32","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0924-8579(98)00020-X","article-title":"In vitro activity of BAY 12-8039, a new fluoroquinolone, against species representative of respiratory tract pathogens","volume":"10","author":"Souli","year":"1998","journal-title":"Int J Antimicrob Agents"},{"key":"10.1006\/pupt.2001.0302_RF33","unstructured":"Kayser, FH, Santanam, P, Huf, E, In: vitro activity of moxifloxacin against invasive pneumococcal strains compared with other antimicrobials. In Adam D, Finch R, eds. Moxifloxacin in practice. Vol 1. Oxford: Maxim Medical, 1999, 39\u201347"},{"key":"10.1006\/pupt.2001.0302_RF34","unstructured":"K\u00f6hler, T, Pech\u00e8re, JC, Bacterial resistance to quinolones. Mechanisms and clinical implications. In: Andriole VT, ed. The quinolones. 2nd ed. San Diego: Academic Press, 1998, 117\u2013142"},{"key":"10.1006\/pupt.2001.0302_RF35","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/jac\/43.suppl_2.51","article-title":"Pharmacodynamics of fluoroquinolones","volume":"43 (Suppl B)","author":"Dalhoff","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1006\/pupt.2001.0302_RF36","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1517\/13543784.10.2.199","article-title":"Advances in DNA gyrase inhibitors","volume":"10","author":"Kim","year":"2001","journal-title":"Exp Opin Invest Drugs"},{"key":"10.1006\/pupt.2001.0302_RF37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0149-2918(00)88266-1","article-title":"Expanded activity and utility of the new fluoroquinolones: a review","volume":"21","author":"Blondeau","year":"1999","journal-title":"Clin Ther"},{"key":"10.1006\/pupt.2001.0302_RF38","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/jac\/40.5.639","article-title":"Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin","volume":"40","author":"Bauernfeind","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"10.1006\/pupt.2001.0302_RF39","first-page":"141","article-title":"The tentative BSAC breakpoint of gemifloxacin, a novel fluoroquinolone","volume":"44 (Suppl A)","author":"Jevons","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1006\/pupt.2001.0302_RF40","first-page":"10","article-title":"In vitro activity of gemifloxacin in comparison to ciprofloxacin, moxifloxacin, ofloxacin and trovafloxacin against Gram-positive and Gram-negative pathogens with reduced suscptibility against ciprofloxacin","volume":"13 (Suppl 2)","author":"Grimm","year":"2000","journal-title":"Rev Esp Quimioterap"},{"key":"10.1006\/pupt.2001.0302_RF41","first-page":"131","article-title":"In vitro activity of gemifloxacin against S. pneumoniae, H. influenzae, M. catarrhalis, L. pneumophila and Chlamydia spp","volume":"44 (Suppl A)","author":"Felmingham","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1006\/pupt.2001.0302_RF42","first-page":"171","article-title":"In vitro activity of sitafloxacin (DU-6859A) and six other fluoroquinolones. Part I: Gram-negative aerobic bacteria","volume":"44 (Suppl A)","author":"Milatovic","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1006\/pupt.2001.0302_RF43","first-page":"171","article-title":"In vitro activity of sitafloxacin (DU-6859A) and six other fluoroquinolones. Part II: Gram-positive cocci","volume":"44 (Suppl A)","author":"Milatovic","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1006\/pupt.2001.0302_RF44","first-page":"27","article-title":"Pharmacokinetic and pharmacodynamic profiles of the new quinolones","volume":"44 (Suppl A)","author":"Turnidge","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1006\/pupt.2001.0302_RF45","first-page":"52","article-title":"Pazufloxacin","volume":"1","author":"Johnson","year":"2000","journal-title":"Curr Opin Invest Drugs"},{"key":"10.1006\/pupt.2001.0302_RF46","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/jac\/40.1.85","article-title":"Ketolides lack inducibility properties of MLSB resistance phenotype","volume":"40","author":"Bonnefoy","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"10.1006\/pupt.2001.0302_RF47","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1021\/jm980240d","article-title":"Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens","volume":"41","author":"Agouridas","year":"1998","journal-title":"J Med Chem"},{"key":"10.1006\/pupt.2001.0302_RF48","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1128\/AAC.42.6.1509","article-title":"In vitro activities of the new ketolide antibiotics HMR 3004 and HMR 3647 against Streptococcus pneumoniae in Germany","volume":"42","author":"Reinert","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1006\/pupt.2001.0302_RF49","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1128\/AAC.42.4.945","article-title":"Antipneumococcal activities of a ketolide (HMR 3647), a streptogramin quinupristin-dalfopristin), a macrolide (erythromycin) and a lincosamide (clindamycin)","volume":"42","author":"Barry","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1006\/pupt.2001.0302_RF50","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1128\/AAC.44.2.414-417.2000","article-title":"In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin and pristinamycin in Streptococcus pneumoniae","volume":"44","author":"Davies","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1006\/pupt.2001.0302_RF51","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1517\/13543784.10.2.353","article-title":"Telithromycin: a new ketolide antimicrobial for treatment of respiratory tract infection","volume":"10","author":"Yassin","year":"2001","journal-title":"Exp Opin Invest Drugs"},{"key":"10.1006\/pupt.2001.0302_RF52","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1128\/AAC.44.6.1562-1567.2000","article-title":"Studies of the novel ketolide ABT-773. Transport, binding to ribosomes and inhibition of protein synthesis of Streptococcus pneumoniae","volume":"44","author":"Capobiano","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1006\/pupt.2001.0302_RF53","first-page":"76","article-title":"Comparison of the in vitro activity of ABT-773, a novel antibacterial ketolide, with erythromycin and ciprofloxacin against respiratory pathogens","volume":"44 (Suppl A)","author":"Nilius","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1006\/pupt.2001.0302_RF54","first-page":"85","article-title":"Activity of the ketolide ABT-773 against recent North American isolates of Streptococcus pneumoniae","volume":"6 (Suppl 1)","author":"Jorgensen","year":"2000","journal-title":"Clin Microbiol Infect"},{"key":"10.1006\/pupt.2001.0302_RF55","unstructured":"Ma, Z, Or, YS, Clark, R et al, Synthesis and antibacterial activity of 6-O-substituted ketolides. In: Abstracts of the 38th Intersci Conf Antimicrob Agents Chemother 1998; F-126"},{"key":"10.1006\/pupt.2001.0302_RF56","unstructured":"Phan, LT, Or, YS, Chen, Y et al, 2-Substituted tricyclic ketolides: new antibacterial macrolides \u2013 synthesis and biological activity. In: Abstracts of the 38th Intersci Conf Antimicrob Agents Chemother 1998; F-127"},{"key":"10.1006\/pupt.2001.0302_RF57","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1128\/AAC.31.11.1791","article-title":"Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721","volume":"31","author":"Slee","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1006\/pupt.2001.0302_RF58","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1086\/318486","article-title":"Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study","volume":"32","author":"Rubinstein","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1006\/pupt.2001.0302_RF59","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1128\/AAC.41.10.2132","article-title":"Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions","volume":"41","author":"Shinabarger","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1006\/pupt.2001.0302_RF60","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1128\/AAC.42.12.3251","article-title":"The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria","volume":"42","author":"Swaney","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1006\/pupt.2001.0302_RF61","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/j.1875-9114.1998.tb03109.x","article-title":"The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials","volume":"18","author":"Dresser","year":"1998","journal-title":"Pharmacotherapy"},{"key":"10.1006\/pupt.2001.0302_RF62","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/jac\/45.6.797","article-title":"Activity of linezolid against Gram-positive cocci possessing genes conferring resistance to protein synthesis inhibitors","volume":"45","author":"Fines","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1006\/pupt.2001.0302_RF63","first-page":"86","article-title":"Multi-center in vitro evaluation of linezolid compared with other antibiotics in The Netherlands","volume":"6 (Suppl 1)","author":"Jansz","year":"2000","journal-title":"Clin Microbiol Infect"},{"key":"10.1006\/pupt.2001.0302_RF64","unstructured":"Pawsey, SD, Daley-Yates, PT, Wajszczuk, CP et al, U-100766 safety, toleration and pharmacokinetics after oral and intravenous administration. In: Program and abstracts of the 1st European Congress of Chemotherapy 1996; F151"},{"key":"10.1006\/pupt.2001.0302_RF65","unstructured":"Hutchinson, DK, Barbachyn, MR, Hester, JB et al, Synthesis and antibacterial activity of azolylphenyloxazolidinones having nitrogen-bound five-membered heterocyclic rings. In: Abstracts of the 38th Intersci Conf Antimicrob Agents Chemother 1998; F-137"},{"key":"10.1006\/pupt.2001.0302_RF66","unstructured":"Glenn, MJ, Allwine, DA, Hutchinson, DK et al, Substituent effects on antibacterial activity of novel highly potent nitrogen-bound azolylphenyl oxazolidiones. In: Abstracts of the 38th Intersci Conf Antimicrob Agents Chemother 1998; F-138"},{"key":"10.1006\/pupt.2001.0302_RF67","unstructured":"Gadwood, RC, Walker, EA, Thomasco, LM et al, Synthesis and antibacterial activity of azolylphenyl oxazolidinones having carbon-bound 1,3-thiazolyl rings. In: Abstracts of the 38th Intersci Conf Antimicrob Agents Chemother 1998; F-139"},{"key":"10.1006\/pupt.2001.0302_RF68","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2165\/00003495-199600511-00008","article-title":"Future prospects and therapeutic potential of streptogramins","volume":"51 (Suppl 1)","author":"Rubinstein","year":"1996","journal-title":"Drugs"},{"key":"10.1006\/pupt.2001.0302_RF69","first-page":"155","article-title":"Recent developments in streptogramin research","volume":"4","author":"Barriere","year":"1998","journal-title":"Curr Pharm Des"},{"key":"10.1006\/pupt.2001.0302_RF70","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/jac\/39.suppl_1.7","article-title":"Inhibition of protein synthesis by streptogramins and related antibiotics","volume":"39 (Suppl A)","author":"Cocito","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"10.1006\/pupt.2001.0302_RF71","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2174\/138161280401221007113202","article-title":"Recent developments in tetracycline antibiotics","volume":"4","author":"Sum","year":"1998","journal-title":"Curr Pharm Des"},{"key":"10.1006\/pupt.2001.0302_RF72","doi-asserted-by":"crossref","first-page":"219S","DOI":"10.1592\/phco.20.14.219S.35046","article-title":"Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent","volume":"20","author":"Projan","year":"2000","journal-title":"Pharmacotherapy"},{"key":"10.1006\/pupt.2001.0302_RF73","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1128\/AAC.43.4.738","article-title":"In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936)","volume":"43","author":"Petersen","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1006\/pupt.2001.0302_RF74","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0960-894X(99)00216-4","article-title":"Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936","volume":"9","author":"Sum","year":"1999","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1006\/pupt.2001.0302_RF75","first-page":"164","article-title":"GAR-936","volume":"2","author":"Johnson","year":"2000","journal-title":"Curr Opin Anti-infect Invest Drugs"},{"key":"10.1006\/pupt.2001.0302_RF76","first-page":"26","article-title":"The renewed challege of \u03b2-lactams to overcome bacterial resistance","volume":"1","author":"Di Modugno","year":"1999","journal-title":"Curr Opin Anti-Infect Investig Drugs"},{"key":"10.1006\/pupt.2001.0302_RF77","unstructured":"Page, M, Bur, D, Hebeisen, P et al, Inhibition of the penicillin-binding proteins of methicillin-resistant Staphylococci by pyrrolidinone-3-ylidenemethyl cephems. In: Abstracts of the 38th Intersci Conf Antimicrob Agents Chemother 1998; F-22"},{"key":"10.1006\/pupt.2001.0302_RF78","unstructured":"Ida, T, Kurazono, M, Yoshida, T et al, ME1209 (CP6679), a new parenteral cephalosporin I. In vitro and in vivo activity against MRSA. In: Abstracts of the 38th Intersci Conf Antimicrob Agents Chemother 1998; F-12"},{"key":"10.1006\/pupt.2001.0302_RF79","unstructured":"Yoshida, T, Ida, I, Kurazono, M et al, ME1209 (CP6679), a new parenteral cephalosporin II. In vitro and in vivo activity against Pseudomonas aeruginosa. In: Abstracts of the 38th Intersci Conf Antimicrob Agents Chemother 1998; F-11"},{"key":"10.1006\/pupt.2001.0302_RF80","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1517\/13543784.9.2.237","article-title":"Novel oral cephalosporins","volume":"9","author":"Cazzola","year":"2000","journal-title":"Exp Opin Invest Drugs"},{"key":"10.1006\/pupt.2001.0302_RF81","unstructured":"Adachi, Y, Nagano, R, Shibata, K, Kato, Y, Hashizume, T, Morishima, H, In vitro activities if J-111,225, J-114,870, J-114,871, novel carbapenems having potent activities against MRSA and Pseudomonas aeruginosa. In: Abstracts of the 38th Intersci Conf Antimicrob Agents Chemother 1998; F-54"},{"key":"10.1006\/pupt.2001.0302_RF82","first-page":"111","article-title":"J-111,225","volume":"1","author":"Andes","year":"1999","journal-title":"Curr Opin Antiinfect Invest Drugs"},{"key":"10.1006\/pupt.2001.0302_RF83","unstructured":"Shibata, K, Nagano, R, Nagami, K et al, Studies on pharmacokinetics and basic toxicity of novel trans-3,5-disubstituted pyrrolidinylthio-1\u03b2-methylcarbapenem. In: Abstracts of the 38th Intersci Conf Antimicrob Agents Chemother 1998; F-53"},{"key":"10.1006\/pupt.2001.0302_RF84","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1128\/AAC.42.1.94","article-title":"In vitro and in vivo antibacterial activities of S-4661, a new carbapenem","volume":"42","author":"Tsuji","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1006\/pupt.2001.0302_RF85","unstructured":"Saito, A, Inamatsu, T, Shimada, J, Clinical studies of S-4661, new parenteral carbapenem antibiotic, in chronic respiratory tract infections. In: Abstracts of the 37th Intersci Conf Antimicrob Agents Chemother 1997; F-219"},{"key":"10.1006\/pupt.2001.0302_RF86","first-page":"101","article-title":"L-084","volume":"1","author":"Andes","year":"1999","journal-title":"Curr Opin AntiInfect Invest Drugs"},{"key":"10.1006\/pupt.2001.0302_RF87","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1128\/AAC.43.3.460","article-title":"In vivo activities of peptidic prodrugs of novel aminomethyl tetrahydrofuranyl-1\u03b2-methylcarbapenems","volume":"43","author":"Weiss","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1006\/pupt.2001.0302_RF88","first-page":"108","article-title":"KR-21,056","volume":"1","author":"Morrissey","year":"1999","journal-title":"Curr Opin Anti-infect Invest Drugs"},{"key":"10.1006\/pupt.2001.0302_RF89","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1128\/AAC.43.8.2010","article-title":"In vitro antibacterial activity of LJC 11,036, an active metabolite of L-084, a new oral carbapenem antibiotic with potent antipneumococcal activity","volume":"43","author":"Hikida","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1006\/pupt.2001.0302_RF90","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1128\/AAC.45.1.203-207.2001","article-title":"In vitro and In vivo antibacterial activities of L-084, a novel oral carbapenem, against causative organisms of respiratory tract infections","volume":"45","author":"Miyazaki","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1006\/pupt.2001.0302_RF91","first-page":"133","article-title":"Overview of recent developments in carbapenem and trinem antibiotics","volume":"2","author":"Andreotti","year":"2000","journal-title":"Curr Opin Anti-infect Invest Drugs"},{"key":"10.1006\/pupt.2001.0302_RF92","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1039\/a704497f","article-title":"The renewed challenge of antibacterial chemotherapy","volume":"2","author":"Niccolai","year":"1997","journal-title":"Chem Comm"},{"key":"10.1006\/pupt.2001.0302_RF93","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1128\/AAC.42.1.173","article-title":"In vitro activity of sanfetrinem and affinity for the penicillin-binding proteins of Streptococcus pneumoniae","volume":"42","author":"Sifaoui","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1006\/pupt.2001.0302_RF94","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1128\/AAC.38.10.2362","article-title":"In vitro activity of the tribactam GV104326 against Gram-positive, Gram-negative, and anaerobic bacteria","volume":"38","author":"Di Modugno","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1006\/pupt.2001.0302_RF95","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0966-842X(97)01051-2","article-title":"Beyond vancomycin: new therapies to meet the challenge of glycopeptide resistance","volume":"5","author":"Nicas","year":"1997","journal-title":"Trends Microbiol"},{"key":"10.1006\/pupt.2001.0302_RF96","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1128\/AAC.37.8.1563","article-title":"Genetics and mechanisms of glycopeptide resistance in enterococci","volume":"37","author":"Arthur","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1006\/pupt.2001.0302_RF97","doi-asserted-by":"crossref","first-page":"677","DOI":"10.7164\/antibiotics.50.677","article-title":"The role of hydrophobic side chains as determinants of antibacterial activity of semisynthetic glycopeptide antibiotics","volume":"50","author":"Allen","year":"1997","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1006\/pupt.2001.0302_RF98","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1126\/science.284.5413.507","article-title":"Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-Ala-D-Ala","volume":"284","author":"Ge","year":"1999","journal-title":"Science"},{"key":"10.1006\/pupt.2001.0302_RF99","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1128\/AAC.41.1.66","article-title":"Molecular interactions of a semisynthetic glycopeptide antibiotic with D-alanyl-D-alanine and D-alanyl-D-lactate residues","volume":"41","author":"Allen","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1006\/pupt.2001.0302_RF100","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/jac\/41.2.273","article-title":"Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin","volume":"41","author":"Harland","year":"1998","journal-title":"J Antimicrob Chemother"},{"key":"10.1006\/pupt.2001.0302_RF101","first-page":"120","article-title":"BI-937","volume":"1","author":"Krivoy","year":"1999","journal-title":"Curr Opin Anti Infect Invest Drugs"},{"key":"10.1006\/pupt.2001.0302_RF102","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1615\/CritRevImmunol.v20.i5.40","article-title":"Cationic antimicrobial peptides and their multifunctional role in the immune system","volume":"20","author":"Scott","year":"2000","journal-title":"Crit Rev Immunol"},{"key":"10.1006\/pupt.2001.0302_RF103","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1128\/AAC.43.6.1317","article-title":"Peptide antibiotics","volume":"43","author":"Hancock","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1006\/pupt.2001.0302_RF104","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1128\/AAC.43.4.782","article-title":"In vitro antibacterial properties of pexiganan, an analog of magainin","volume":"43","author":"Ge","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1006\/pupt.2001.0302_RF105","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1128\/AEM.63.3.1155-1159.1997","article-title":"Protamine-induced permeabilization of cell envelopes of Gram-positive and Gram-negative bacteria","volume":"63","author":"Johansen","year":"1997","journal-title":"Appl Environ Microbiol"},{"key":"10.1006\/pupt.2001.0302_RF106","first-page":"140","article-title":"Cationic antimicrobial peptide antibiotics","volume":"2","author":"Hancock","year":"2000","journal-title":"Curr Opin Anti-infect Invest Drugs"},{"key":"10.1006\/pupt.2001.0302_RF107","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/(SICI)1097-0282(1998)47:6<451::AID-BIP4>3.0.CO;2-F","article-title":"Mode of action of linear amphipathic ?-helical antimicrobial peptides","volume":"47","author":"Oren","year":"1998","journal-title":"Biopolymers"},{"key":"10.1006\/pupt.2001.0302_RF108","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1517\/13543784.10.2.321","article-title":"Granulysin: a novel antimicrobial","volume":"10","author":"Krensky","year":"2001","journal-title":"Exp Opin Investig Drugs"},{"key":"10.1006\/pupt.2001.0302_RF109","first-page":"140","article-title":"Cationic antimicrobial peptide antibiotics","volume":"2","author":"Hancock","year":"2000","journal-title":"Curr Opin AntiInfect Invest Drugs"},{"key":"10.1006\/pupt.2001.0302_RF110","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1517\/13543784.8.8.1223","article-title":"Daptomycin: a novel agent for Gram-positive infections","volume":"8","author":"Tally","year":"1999","journal-title":"Exp Opin Invest Drugs"},{"key":"10.1006\/pupt.2001.0302_RF111","unstructured":"Jacobus, NV, McDermott, L, Lonks, JR, Boyce, JM, Snydman, DR, In vitro activity of daptomycin against resistant Gram-positive pathogens. In: Abstracts of the 38th Intersci Conf Antimicrob Agents Chemother 1998; F-112"},{"key":"10.1006\/pupt.2001.0302_RF112","unstructured":"Rybak, MJ, Hershberger, E, Moldovan, T, Comparative in vitro activity of daptomycin versus vancomycin, linezolid, and synercid against methicillin-resistant and susceptible staphylococci, vancomycin-intermediate susceptible Staphylococcus aureus (VISA) and vancomycin-susceptible Staphylococcus aureus. In; Abstracts of the 38th Intersci Conf Antimicrob Agents Chemother 1998; C-146"},{"key":"10.1006\/pupt.2001.0302_RF113","unstructured":"Oliver, N, Andrew, T, Silverman, JA, Tally, FP, In vitro studies on resistance to lipopeptide antibiotic daptomycin. In: Abstracts of the 38th Intersci Conf Antimicrob Agents Chemother 1998; F-117"},{"key":"10.1006\/pupt.2001.0302_RF114","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1128\/AAC.34.6.1220","article-title":"Lipoteichoic acid as a new target for activity of antibiotics: mode of action of daptomycin (LY146032)","volume":"34","author":"Canepari","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1006\/pupt.2001.0302_RF115","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1128\/AAC.35.11.2282","article-title":"Daptomycin disrupts membrane potential in growing Staphylococcus aureus","volume":"35","author":"Alborn","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1006\/pupt.2001.0302_RF116","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/jac\/43.4.447","article-title":"Inhibitor-resistant TEM \u03b2-lactamases: phenotypic, genetic and biochemical characteristics","volume":"43","author":"Chaibi","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1006\/pupt.2001.0302_RF117","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2174\/0929867305666220319110127","article-title":"\u03b2-Lactamase inhibitors: agents to overcome bacterial resistance","volume":"5","author":"Maiti","year":"1998","journal-title":"Curr Med Chem"},{"key":"10.1006\/pupt.2001.0302_RF118","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1159\/000239464","article-title":"Susceptibility of clinical isolates to expanded-spectrum \u00df-lactams alone and in the presence of \u03b2-lactamase inhibitors","volume":"42","author":"Qadri","year":"1996","journal-title":"Chemotherapy"},{"key":"10.1006\/pupt.2001.0302_RF119","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1128\/AAC.41.2.475","article-title":"Comparative evaluation of the inhibitory activities of the novel penicillanic acid sulfone Ro 48-1220 against \u03b2-lactamases that belong to groups 1, 2b, and 2be","volume":"41","author":"Tzouvelekis","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1006\/pupt.2001.0302_RF120","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1128\/AAC.43.8.1895","article-title":"In vitro and in vivo activities of Syn2190, a novel \u03b2-lactamase inhibitor","volume":"43","author":"Nishida","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1006\/pupt.2001.0302_RF121","first-page":"289","article-title":"Inhibition of IMP-1 metallo-\u00df -lactamase and sensitization of IMP-1-producing bacteria by thioester derivatives (dagger)","volume":"179","author":"Hammond","year":"1999","journal-title":"FEMS Microbiol Lett"},{"key":"10.1006\/pupt.2001.0302_RF122","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1248\/bpb.21.678","article-title":"Screening of an inhibitor of the tetracycline efflux pump in a tetracycline-resistant clinical-isolate of Staphylococcus aureus 743","volume":"21","author":"Hirata","year":"1998","journal-title":"Biol Pharm Bull"},{"key":"10.1006\/pupt.2001.0302_RF123","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1128\/AAC.42.1.65","article-title":"Expression of Pseudomonas aeruginosa multidrug efflux pumps MexA-MexB-OprM and MexC-MexD-OprJ in a multidrug-sensitive Escherichia coli strain","volume":"42","author":"Srikumar","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1006\/pupt.2001.0302_RF124","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1128\/AAC.43.2.400","article-title":"Interplay between chromosomal \u03b2-lactamase and the MexAB-OprM efflux system in intrinsic resistance to \u03b2-lactams in Pseudomonas aeruginosa","volume":"43","author":"Masuda","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1006\/pupt.2001.0302_RF125","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/jac\/33.6.1091","article-title":"Bacterial resistance mechanisms as therapeutic targets","volume":"33","author":"Coleman","year":"1994","journal-title":"J Antimicrob Chemother"},{"key":"10.1006\/pupt.2001.0302_RF126","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2165\/00044011-199816040-00008","article-title":"Pharmacokinetics and pharmacodynamics of newer oral cephalosporins: implication for treatment of community-acquired lower respiratory tract infections","volume":"16","author":"Cazzola","year":"1998","journal-title":"Clin Drug Invest"},{"key":"10.1006\/pupt.2001.0302_RF127","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1006\/pulp.1994.1017","article-title":"Problems and prospectives in the antibiotic treatment of lower respiratory tract infections","volume":"7","author":"Cazzola","year":"1994","journal-title":"Pulm Pharmacol"},{"key":"10.1006\/pupt.2001.0302_RF128","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1517\/13543784.6.2.151","article-title":"Oxazolidinone antibacterial agents: development of the clinical candidates eperezolid and linezolid","volume":"6","author":"Zurenko","year":"1997","journal-title":"Expert Opin Invest Drugs"},{"key":"10.1006\/pupt.2001.0302_RF129","unstructured":"White, P, Antibiotics, market review and development trends, Financial Times Business Ltd, 1999"}],"container-title":["Pulmonary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553901903025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553901903025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,12,30]],"date-time":"2023-12-30T02:07:50Z","timestamp":1703902070000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553901903025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,10]]},"references-count":129,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2001,10]]}},"alternative-id":["S1094553901903025"],"URL":"https:\/\/doi.org\/10.1006\/pupt.2001.0302","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2001,10]]}}}